SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 118 filers reported holding SYNAGEVA BIOPHARMA CORP in Q2 2014. The put-call ratio across all filers is 1.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2015 | $7,995,000 | +35.0% | 81,971 | +28.4% | 0.02% | +26.7% |
Q4 2014 | $5,924,000 | +31.4% | 63,848 | -2.6% | 0.02% | +36.4% |
Q3 2014 | $4,508,000 | -19.4% | 65,548 | +22.9% | 0.01% | -21.4% |
Q2 2014 | $5,590,000 | +11.0% | 53,342 | -12.1% | 0.01% | 0.0% |
Q1 2014 | $5,034,000 | +24.2% | 60,673 | -3.1% | 0.01% | +16.7% |
Q4 2013 | $4,052,000 | – | 62,607 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 10,660,432 | $989,182,000 | 10.10% |
BB BIOTECH AG | 1,130,476 | $104,897,000 | 3.40% |
BLUE JAY CAPITAL MANAGEMENT, LLC | 80,000 | $7,423,000 | 3.31% |
Opus Point Partners Management, LLC | 20,002 | $1,856,000 | 1.84% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,847,094 | $356,972,000 | 1.77% |
SECTORAL ASSET MANAGEMENT INC | 363,884 | $33,765,000 | 1.52% |
Cormorant Asset Management, LP | 100,000 | $9,279,000 | 1.43% |
Tekla Capital Management LLC | 223,020 | $20,694,000 | 0.97% |
Lamond Capital Partners LLC | 15,390 | $1,428,000 | 0.94% |
Squarepoint Ops LLC | 6,700 | $622,000 | 0.60% |